Allogene Therapeutics: Q4 Earnings Snapshot
Allogene Therapeutics: Q3 Earnings Snapshot
Wall Street price targets suggest this stock can rocket more than 400% higher.
/PRNewswire/ -- Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric...
Allogene Therapeutics: Q2 Earnings Snapshot
BYND, BTAI, and ALLO stand out as high short-interest stocks to watch due to their potential for price fluctuations and short-squeeze opportunities.
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.